Literature DB >> 27116846

Evidence-Based Management of Patients with 45,X/46,XY Gonadal Dysgenesis and Male Sex Assignment: from Infancy to Adulthood.

Johanna Viau Colindres, Marni Axelrad, Laurence McCullough, E O'Brian Smith, Gene O Huang, Duong D Tu, Jennifer L Bercaw-Pratt, Min-Jye Cheni, Meenal Mendiratta, Sheila Gunn, Reid Sutton, Charles Macias, Lefkothea P Karaviti.   

Abstract

45,X/46,XY gonadal dysgenesis is a disorder of sexual differentiation with a wide clinical presentation, ranging from Turner-like females to individuals with genital ambiguity to azoospermic but otherwise normal-appearing males. Hence, patients can be assigned female or male sex. Female patients are managed according to the Turner Syndrome Guidelines, whereas males are managed on a case-by-case basis. Male patients present with multiple medical challenges: undervirilization, hypogonadism, gonadoblastoma risk, and short stature. Many require surgeries and hormonal treatments that are time-sensitive and irreversible. Nonetheless, these therapeutic decisions are made without evidence-based guidelines. This review describes the medical concerns and possible interventions in male patients with 45,X/46,XY dysgenesis for each stage of development. Interventions should be addressed within a patient-centered framework by a multidisciplinary team and after thorough discussion with the family. We use the GRADE system to appraise the existing evidence and provide recommendations based on the available evidence.

Entities:  

Mesh:

Year:  2016        PMID: 27116846

Source DB:  PubMed          Journal:  Pediatr Endocrinol Rev        ISSN: 1565-4753


  2 in total

1.  Growth data and tumour risk of 32 Chinese children and adolescents with 45,X/46,XY mosaicism.

Authors:  Lili Pan; Zhe Su; Jianming Song; Wanhua Xu; Xia Liu; Longjiang Zhang; Shoulin Li
Journal:  BMC Pediatr       Date:  2019-05-06       Impact factor: 2.125

2.  Discordant sex between fetal screening and postnatal phenotype requires evaluation.

Authors:  Heather M Byers; Whitney Neufeld-Kaiser; Edith Y Chang; Karen Tsuchiya; Erin S Oehler; Margaret P Adam
Journal:  J Perinatol       Date:  2018-11-21       Impact factor: 2.521

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.